Popular Diabetes Drugs May Help Combat Multiple Addictions, Major Study Shows

A groundbreaking study of over 600,000 veterans found that popular diabetes medications like Ozempic and Mounjaro may significantly reduce the risk of developing addictions to alcohol, drugs, and nicotine. The research suggests these medications could potentially help the 48 million Americans struggling with substance abuse disorders.

Popular diabetes medications that have transformed obesity treatment could offer new hope in battling substance abuse disorders, according to groundbreaking research involving more than 600,000 patients.

A comprehensive study released Wednesday in a medical journal examined electronic health records from U.S. Veterans Affairs patients diagnosed with diabetes. Researchers discovered that individuals receiving treatments like Ozempic and Mounjaro showed significantly lower rates of developing dependencies on alcohol, nicotine, cocaine, opioids and other substances compared to patients using alternative diabetes medications.

Among patients already struggling with addiction, these GLP-1 medications correlated with reduced hospitalization rates, fewer overdoses and lower death rates, the research revealed.

While the findings suggest these weight-loss drugs could address the fundamental brain mechanisms behind cravings affecting over 48 million Americans with substance abuse problems, the study stops short of proving causation.

“They’re actually working against the root cause of all these different addictions,” explained Dr. Ziyad Al-Aly, who led the research and serves as chief researcher at the VA St. Louis Health Care System.

Earlier research had indicated that GLP-1 medications, scientifically known as glucagon-like peptide-1 receptor agonists, might combat addiction by influencing brain reward systems. However, those investigations were typically smaller in scope and focused on single substances.

This expanded analysis, among the most comprehensive conducted to date, saw Al-Aly and his research team examine electronic medical records spanning three years from more than 600,000 Veterans Affairs diabetes patients. They contrasted outcomes between patients prescribed GLP-1 drugs and those receiving alternative blood sugar-lowering treatments.

Researchers organized participants into seven separate studies examining addiction development risks across various substances including alcohol, cannabis, cocaine, nicotine and opioids. An additional study evaluated specific health risks among individuals with pre-existing addictions using different medication types.

The investigation revealed that patients beginning GLP-1 treatment faced reduced addiction development risks across multiple substances. When compared to alternative medications, GLP-1 users showed decreased addiction risks of 18% for alcohol, 14% for cannabis, 20% for both cocaine and nicotine, and 25% for opioids.

For patients already battling substance abuse disorders, initiating GLP-1 treatment correlated with 31% fewer emergency room visits, 26% fewer hospitalizations, 25% reduced suicidal ideation or attempts, 39% fewer overdoses, and 50% lower mortality rates.

The study calculated that GLP-1 drug usage likely prevented approximately seven substance abuse cases and 12 serious harm incidents per 1,000 users across the three-year period, Al-Aly reported.

The research has notable limitations: it occurred within the VA healthcare system, serving a demographic that’s predominantly older, white and male, though Al-Aly noted consistent results among more than 35,000 female participants. The data also exclusively covers diabetes patients rather than the broader population.

Researchers couldn’t control for certain variables like economic status or personal lifestyle decisions that might influence outcomes. The analysis compared GLP-1 effects against other medications rather than no treatment at all.

As an observational investigation, the study demonstrates correlation between GLP-1 usage and reduced substance abuse risks and consequences, rather than proving the medications directly caused these improvements.

Dr. Lorenzo Leggio, a National Institute on Drug Abuse clinical director not involved in the research, called the discoveries remarkable.

“Even though we don’t fully understand the mechanism, somehow the GLP-1 system is tackling addiction biology and the foundational system that underlies all these disorders,” Leggio stated.

Clinical trials for diabetes and weight management have demonstrated that GLP-1 drugs influence gut and brain hormones controlling appetite and satiety, reducing what researchers call “food noise” or persistent food thoughts. Similarly, this study suggests the medications might diminish “alcohol or drug noise,” according to Leggio.

Dr. Anna Lembke, a Stanford University addiction medicine expert, expressed enthusiasm about mounting evidence that GLP-1s could prevent substance abuse disorders.

“We haven’t really had a new tool in our toolbox from a pharmacotherapy perspective to treat addiction in a long time,” Lembke observed, noting that some addiction specialists already prescribe GLP-1s off-label when conventional treatments prove ineffective.

However, she warned that GLP-1 medications don’t produce uniform results across all users and carry risks requiring careful consideration against potential advantages.

Al-Aly emphasized that these findings alone don’t warrant prescribing GLP-1 drugs for preventing or treating substance abuse disorders. Such evidence would require randomized controlled clinical trials directly comparing drug usage against placebo treatments. Several such studies are currently underway, Leggio confirmed.

The ultimate objective involves discovering innovative approaches to treating addictions, which represent major contributors to illness and death globally.

“The consequence in terms of chronic disease of these addictive drugs is actually gigantic in our society,” Leggio concluded.